Integer Holdings Co. (NYSE:ITGR) Stock Position Raised by Yousif Capital Management LLC

Yousif Capital Management LLC lifted its holdings in shares of Integer Holdings Co. (NYSE:ITGR) by 2.3% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 17,013 shares of the medical equipment provider’s stock after purchasing an additional 386 shares during the quarter. Yousif Capital Management LLC’s holdings in Integer were worth $1,686,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Blue Trust Inc. grew its position in shares of Integer by 483.3% during the 4th quarter. Blue Trust Inc. now owns 455 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 377 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in shares of Integer by 66.6% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,461 shares of the medical equipment provider’s stock valued at $115,000 after buying an additional 584 shares during the last quarter. Van ECK Associates Corp boosted its stake in Integer by 22.0% during the 3rd quarter. Van ECK Associates Corp now owns 1,733 shares of the medical equipment provider’s stock valued at $136,000 after purchasing an additional 313 shares during the period. Strs Ohio boosted its stake in Integer by 54.5% during the 4th quarter. Strs Ohio now owns 1,700 shares of the medical equipment provider’s stock valued at $168,000 after purchasing an additional 600 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in Integer during the 3rd quarter valued at about $182,000. Institutional investors own 99.29% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on ITGR. KeyCorp boosted their target price on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research note on Tuesday, April 9th. CL King initiated coverage on shares of Integer in a research note on Thursday, March 14th. They set a “buy” rating and a $137.00 target price for the company. Bank of America raised shares of Integer from a “neutral” rating to a “buy” rating and upped their price target for the stock from $105.00 to $135.00 in a research note on Monday, April 15th. Finally, Benchmark reaffirmed a “buy” rating and issued a $130.00 price target on shares of Integer in a research note on Friday, April 26th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $120.50.

Integer Trading Down 1.7 %

Shares of NYSE:ITGR opened at $109.77 on Thursday. Integer Holdings Co. has a twelve month low of $69.40 and a twelve month high of $123.99. The firm has a market cap of $3.68 billion, a P/E ratio of 37.98, a P/E/G ratio of 1.69 and a beta of 1.10. The company has a 50 day moving average of $113.86 and a 200-day moving average of $100.67. The company has a current ratio of 3.32, a quick ratio of 2.01 and a debt-to-equity ratio of 0.76.

Integer (NYSE:ITGR) last released its earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 EPS for the quarter, beating the consensus estimate of $1.12 by $0.02. Integer had a net margin of 6.01% and a return on equity of 11.25%. The business had revenue of $414.80 million during the quarter, compared to analyst estimates of $412.78 million. During the same period in the prior year, the business earned $0.87 earnings per share. The business’s quarterly revenue was up 9.5% on a year-over-year basis. As a group, analysts anticipate that Integer Holdings Co. will post 5.27 earnings per share for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.